Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Ethacrynic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSTP1 | P09211 | 14/20 | 0.97 |
| ▸ | GSTA1 | P08263 | 8/20 | 0.97 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.97 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.97 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.97 |
| ▸ | MEN1 | O00255 | 1/20 | 0.97 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.97 |
| ▸ | PLIN1 | O60240 | 1/20 | 0.97 |
| ▸ | LMNA | P02545 | 1/20 | 0.97 |
| ▸ | TP53 | P04637 | 1/20 | 0.97 |
| ▸ | MAPT | P10636 | 1/20 | 0.97 |
| ▸ | HSPD1 | P10809 | 1/20 | 0.97 |
| ▸ | TSHR | P16473 | 1/20 | 0.97 |
| ▸ | HTT | P42858 | 1/20 | 0.97 |
| ▸ | RECQL | P46063 | 1/20 | 0.97 |
| ▸ | MAP2K6 | P52564 | 1/20 | 0.97 |
| ▸ | HSPE1 | P61604 | 1/20 | 0.97 |
| ▸ | GSTO1 | P78417 | 1/20 | 0.97 |
| ▸ | PLIN5 | Q00G26 | 1/20 | 0.97 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.97 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ethacrynic Acid SCHEMBL2482896 | 1.00 | GSTP1 (0.97) | GSTP1GSTA1CYP2C9ALDH1A1NPSR1 | |
| Ethacrynic Acid SCHEMBL9108011 | 0.99 | GSTP1 (1.00) | GSTP1GSTA1CYP2C9ALDH1A1NPSR1 | |
| Ethacrynic Acid SCHEMBL26353 | 0.99 | GSTP1 (1.00) | GSTP1GSTA1CYP2C9ALDH1A1NPSR1 | |
| Ethacrynic Acid SCHEMBL29384243 | 0.99 | GSTP1 (1.00) | GSTP1GSTA1CYP2C9ALDH1A1NPSR1 | |
| Ethacrynic Acid SCHEMBL3713733 | 0.97 | GSTP1 (0.97) | GSTP1GSTA1CYP2C9ALDH1A1NPSR1 | |
| Ethacrynic Acid SCHEMBL8907134 | 0.93 | GSTP1 (0.84) | GSTP1GSTA1CYP2C9ALDH1A1NPSR1 | |
| Ethacrynic Acid SCHEMBL18263238 | 0.91 | GSTP1 (0.86) | GSTP1GSTA1CYP2C9ALDH1A1NPSR1 | |
| SCHEMBL10543330 | 0.88 | GSTP1 (0.81) | GSTP1GSTA1CYP2C9ALDH1A1NPSR1 | |
| SCHEMBL10001217 | 0.88 | GSTP1 (0.81) | GSTP1GSTA1CYP2C9ALDH1A1NPSR1 | |
| SCHEMBL9717560 | 0.88 | GSTP1 (0.80) | GSTP1GSTA1CYP2C9ALDH1A1NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 397 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2277520-A2 | A pharmaceutical composition for angiotensin ii-mediated diseases | Takeda Pharmaceutical Company Limited (JP) | 2011-01-26 | — | — | EP | claimed |
| EP-1844774-A2 | A pharmaceutical composition for angiotensin II-mediated diseases | Takeda Pharmaceutical Company Limited (JP) | 2007-10-17 | — | — | EP | claimed |
| EP-1306089-A1 | Combination of benzimidazoles having angiotensin-II antagonistic activity with diuretics or calcium antagonists | Takeda Chemical Industries, Ltd. (JP) | 2003-05-02 | — | — | EP | claimed |
| EP-1306088-A1 | Combination of a benzimidazole having angiotensin-II antagonistic activity with a diuretic | Takeda Chemical Industries, Ltd. (JP) | 2003-05-02 | — | — | EP | claimed |
| US-20010011098-A1 | Pharmaceutical composition for angiotensin II-mediated diseases | TAKEDA PHARMACEUTICAL COMPANY, LIMITED (JP) | 2001-08-02 | — | — | US | claimed |
| US-20010004640-A1 | Pharmaceutical composition for angiotensin II-mediated diseases | TAKEDA PHARMACEUTICAL COMPANY, LIMITED (JP) | 2001-06-21 | — | — | US | claimed |
| EP-0617001-B1 | Phenoxyphenylacetic acid derivatives | MERCK & CO INC (US) | 2000-01-26 | — | — | EP | claimed |
| EP-0753301-A1 | Combination of benzimidazoles having angiotensin-II antagonistic activity with diuretics | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1997-01-15 | — | — | EP | claimed |
| US-5538991-A | TREATMENT OF HYPERTENSION, CARDIOVASCULAR DISORDERS, PROSTATE HYPERPLASIA OR ANTIINFLAMMATORY AGENTS | MERCK & CO., INC. (US) | 1996-07-23 | — | — | US | claimed |
| WO-1996008486-A1 | ENDOTHELIN ANTAGONISTS BEARING 5-MEMBERED HETEROCYCLIC AMIDES | MERCK & CO., INC. (US) | 1996-03-21 | — | — | WO | claimed |
| EP-0156318-A2 | C-terminal amide cyclic renin inhibitors containing peptide isosteres | MERCK & CO. INC. (US) | 1985-10-02 | — | — | EP | claimed |
| EP-0156322-A2 | Renin inhibitors containing peptide isosteres | MERCK & CO. INC. (US) | 1985-10-02 | — | — | EP | claimed |
| EP-0032725-B1 | NOVEL ALDEHYDE ADDUCTS OF TRIAMTERENE AND A PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | MERCK & CO. INC. (US) | 1985-05-08 | — | — | EP | claimed |
| EP-0129189-A2 | Renin inhibitors containing a C-terminal amide cycle and compositions and combinations containing the same | MERCK & CO. INC. (US) | 1984-12-27 | — | — | EP | claimed |
| US-4472380-A | CARBOXYALKYL DIPEPTIDE DERIVATIVES | MERCK & CO., INC. (US) | 1984-09-18 | — | — | US | claimed |
| EP-0107095-A1 | 1-N-alkylcarboxy-benzofused lactams useful as antihypertensive agents | MERCK & CO. INC. (US) | 1984-05-02 | — | — | EP | claimed |
| EP-0081094-A1 | Substituted omega-amino-carboxymethyldipeptide antihypertensive agents | MERCK & CO. INC. (US) | 1983-06-15 | — | — | EP | claimed |
| EP-0079522-A1 | N-Carboxymethyl(amidino)lysyl-proline antihypertensive agents | MERCK & CO. INC. (US) | 1983-05-25 | — | — | EP | claimed |
| US-4285947-A | DIURETICS, HYPOTENSIVES | INTERX RESEARCH CORPORATION (US) | 1981-08-25 | — | — | US | claimed |
| EP-0032725-A1 | Novel aldehyde adducts of triamterene and a pharmaceutical composition containing the same | MERCK & CO. INC. (US) | 1981-07-29 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010011098-A1 | Pharmaceutical composition for angiotensin II-mediated diseases | AGTR1, REN, AGTR2 | GSTP1 1714/4885GSTA1 1541/4885CYP2C9 1492/4885 |
| US-20010004640-A1 | Pharmaceutical composition for angiotensin II-mediated diseases | AGTR1, REN, AGTR2 | GSTP1 1714/4885GSTA1 1541/4885CYP2C9 1492/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.